Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Transaction in own shares

07/26/2021 | 12:01pm EDT
Arix Bioscience PLC (ARIX) 
Transaction in own shares 
26-Jul-2021 / 17:00 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
 
Arix Bioscience plc 
 
Transaction in own shares 
 
LONDON, 26 July 2021: Arix Bioscience plc ("Arix" or "the Company") (LSE: ARIX), a global venture capital company 
focused on investing in and building breakthrough biotech companies, today announces that it purchased the following 
number of its ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as 
part of a buyback programme announced on 22 March 2021. 
 
Date of purchase                      26 July 2021 
Aggregate number of shares purchased  18,000 
Highest price paid per share          175.00p 
Lowest price paid per share           175.00p 
Average price paid per share          175.00p 

Arix intends to retain the purchased shares in treasury.

Following settlement of the above purchase, Arix will have 130,952,800 ordinary shares of 0.001 pence each in issue (excluding 4,656,853 ordinary shares of 0.001p each held in treasury). This number represents the total voting rights in Arix and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), the schedule below contains detailed information of the individual trades made by Jefferies International Limited as part of the buyback programme.

[ENDS]

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

Optimum Strategic Communications

Mary Clark, Manel Mateus

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

Transaction Date Transaction Time Volume Price (GBp) Platform              Transaction Reference Number 
26/07/2021       08:04:14         18,000 175.00      London Stock Exchange 00253150916TRLO1 ----------------------------------------------------------------------------------------------------------------------- 
ISIN:           GB00BD045071 
Category Code:  POS 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 2.4. Acquisition or disposal of the issuer's own shares 
Sequence No.:   118515 
EQS News ID:    1221755 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1221755&application_name=news 
 

(END) Dow Jones Newswires

July 26, 2021 12:00 ET (16:00 GMT)

All news about ARIX BIOSCIENCE PLC
09/03VC DAILY : Question: What Is Driving Startup -2-
DJ
09/02ARIX BIOSCIENCE : To Invest $11 Million In Disc Medicine
MT
09/02Arix Bioscience participates in USD90 million Series B financing for Disc Med..
DJ
09/02Disc Medicine, Inc. announced that it has received $90 million in funding fro..
CI
09/01Total Voting Rights
DJ
08/31Transaction in own shares
DJ
08/16Transaction in own shares
DJ
08/16Director/PDMR Shareholding
DJ
08/13Transaction in own shares
DJ
08/13ARIX BIOSCIENCE : Interim Results for the Six Months Ended 30 June 2021
AQ
More news
Financials
Sales 2021 0,50 M 0,69 M 0,69 M
Net income 2021 37,7 M 51,8 M 51,8 M
Net cash 2021 146 M 200 M 200 M
P/E ratio 2021 5,67x
Yield 2021 -
Capitalization 205 M 282 M 282 M
EV / Sales 2021 119x
EV / Sales 2022 98,9x
Nbr of Employees 12
Free-Float 72,2%
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | ARIX | GB00BD045071 | MarketScreener
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 164,00 GBX
Average target price 221,50 GBX
Spread / Average Target 35,1%
EPS Revisions
Managers and Directors
Robert William Henry Lyne CEO, COO, Secretary, Director & General Counsel
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Giles Francis Bertram Kerr Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ARIX BIOSCIENCE PLC-25.11%282
INVESTOR AB (PUBL)33.05%69 913
CK HUTCHISON HOLDINGS LIMITED-2.96%25 894
HAL TRUST32.13%15 487
AB INDUSTRIVÄRDEN (PUBL)7.73%14 531
LIFCO AB (PUBL)62.86%13 413